A method of manufacturing a placental product comprising the steps of: a. obtaining a placenta; b. selectively depleting the amniotic membrane of at least 50% of one or more types of immunogenic cells, wherein i. the one or more types of immunogenic cells comprise functional CD14+ macrophages; and ii. the step of selective depletion preserves the viability of a substantial portion of native therapeutic cells selected from MSCs, fibroblasts, epithelial cells, stromal cells, and a combination thereof; and iii. optionally, removing substantially all vascularized tissue or vascularized tissue-derived immunogenic cells from the placenta, or amniotic membrane thereof; thereby providing a amniotic membrane, wherein the amniotic membrane comprises viable therapeutic cells, wherein the viable therapeutic cells are native to the amniotic membrane and are one or more of MSCs, fibroblasts, epithelial cells, and stromal cells; and c. cryopreserving the amniotic membrane in a cryopreservation medium, wherein said depleting step comprises selectively killing or inactivating the functional CD14+ macrophages, wherein said depleting step comprises refrigerating the placenta for a period of time before the step of cryopreservation, wherein the refrigerating comprises incubating the placenta in the cryopreservation medium for the period of time at a temperature of 2°C to 8°C, wherein the period of time is a period of time sufficient to allow the placenta or amniotic membrane thereof to equilibrate. a. obtaining a placenta; b. selectively depleting the amniotic membrane of at least 50% of one or more types of immunogenic cells, wherein i. the one or more types of immunogenic cells comprise functional CD14+ macrophages; and ii. the step of selective depletion preserves the viability of a substantial portion of native therapeutic cells selected from MSCs, fibroblasts, epithelial cells, stromal cells, and a combination thereof; and iii. optionally, removing substantially all vascularized tissue or vascularized tissue-derived immunogenic cells from the placenta, or amniotic membrane thereof; thereby providing a amniotic membrane, wherein the amniotic membrane comprises viable therapeutic cells, wherein the viable therapeutic cells are native to the amniotic membrane and are one or more of MSCs, fibroblasts, epithelial cells, and stromal cells; and i. the one or more types of immunogenic cells comprise functional CD14+ macrophages; and ii. the step of selective depletion preserves the viability of a substantial portion of native therapeutic cells selected from MSCs, fibroblasts, epithelial cells, stromal cells, and a combination thereof; and iii. optionally, removing substantially all vascularized tissue or vascularized tissue-derived immunogenic cells from the placenta, or amniotic membrane thereof; c. cryopreserving the amniotic membrane in a cryopreservation medium, wherein said depleting step comprises selectively killing or inactivating the functional CD14+ macrophages, wherein said depleting step comprises refrigerating the placenta for a period of time before the step of cryopreservation, wherein the refrigerating comprises incubating the placenta in the cryopreservation medium for the period of time at a temperature of 2°C to 8°C, wherein the period of time is a period of time sufficient to allow the placenta or amniotic membrane thereof to equilibrate.